Influences on bone mineral density in Malaysian premenopausal systemic lupus erythematosus patients on corticosteroids

Abstract

The aim of this study was to assess the bone mineral density (BMD) of premenopausal patients with systemic lupus erythematosus (SLE) on corticosteroids (CS) and to determine the influence of CS and other risk factors on BMD. A total of 98 premenopausal patients with SLE were recruited from outpatient clinics in two teaching hospitals. Risk factors for osteoporosis were determined, and BMD was measured using dual-energy x-ray absorptiometry. The mean age of the patients was 30.05 ± 7.54 years. The mean dose of prednisolone at time of BMD measurement was 18.38 ± 10.85 mg daily. Median duration of CS use was 2.5 years (range 0–20). Median cumulative dose of CS was 9.04 g (range 0.28–890.0). Six patients (6.1%) had osteoporosis, 41 (41.9%) had osteopenia and 51 (52.0%) had normal BMD. Lumbar spine T score correlated with cumulative CS dose (P = 0.019). Duration of CS intake correlated with femoral neck T score (P = 0.04) and trochanter T score (P = 0.008). There was no correlation between BMD and race, SLE Disease Activity Index score, smoking and self-reported calcium intake or exercise. Only 52% of these patients had normal BMD. The duration and cumulative dose of CS intake was significantly correlated to BMD, but not the other commonly assessed risk factors. These findings suggest that premenopausal patients with SLE on CS should have their BMD measured at regular intervals to fully assess their osteoporosis risk.

Keywords

bone mineral density corticosteroids osteoporosis SLE

Get full access to this article

View all access options for this article.

References

1 Ramsey-Goldman R Dunn JE Huang CF . Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum 1999; 42: 882–890.

2 Dhillon VB Davies MC Hall ML . Assessment of effect of oral steroids on bone mineral density in systemic lupus erythematosus: a preliminary study with dual energy x ray absorptiometry. Ann Rheum Dis 1990; 49: 624–626.

3 Kalla AA Fataar AB Jessop SJ Bewerunge L . Loss of trabecular bone mineral density in systemic lupus erythematosus. Arthritis Rheum 1993; 36: 1726–1734.

4 Pons F Peris P Guanabens N . The effect of systemic lupus erythematosus and long-term steroid therapy on bone mass in premenopausal women. Br J Rheumatol 1995; 34: 742–746.

5 Formiga F Moga I Nolla JM Pac M Mitjavila F Roig-Escofet D . Loss of bone mineral density in premenopausal women with systemic lupus erythematosus. Ann Rheum Dis 1995; 54: 274–276.

6 Houssiau FA Lefèbvre C Depresseux G Lambert M Devogelaer J-P Nagant de Deuxchaisnes C . Trabecular and cortical bone loss in systemic lupus erythematosus. Br J Rheumatol 1996; 35: 244–247.

7 Sinigaglia L Varenna M Binelli L . Determinants of bone mass in systemic lupus erythematosus: a cross sectional study on premenopausal women. J Rheumatol 1999; 26: 1280–1284.

8 Li EK Tam LS Young RP Ko GTC Li M Lau EMC . Loss of bone mineral density in Chinese pre-menopausal women with systemic lupus erythematosus treated with corticosteroids. Br J Rheumatol 1998; 37: 405–410.

9 Jardinet D Lefèbvre C Depresseux G Lambert M Devogelaer J-P Houssiau FA . Longitudinal analysis of bone mineral density in pre-menopausal female SLE patients: deleterious role of glucocorticoid therapy at the lumbar spine. Rheumatology 2000; 39: 389–392.

10.

10 Uaratanawong S Deesomchoke U Lertmaharit S Uaratanawong S . Bone mineral density in premenopausal women with systemic lupus erythematosus. J Rheumatol 2003; 30: 2365–2368.

11.

11 Coimbra IB Costallat LTL . Bone mineral density in systemic lupus erythematosus and its relation to age at disease onset, plasmatic estradiol and immunosuppressive therapy. Joint Bone Spine 2003; 70: 40–45.

12.

12 Tan EM Cohen AS Fries JF . The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1275.

13.

13 Bombardier C Gladman DD Urowitz MB Caron D Chang CH . Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630–640.

14.

14 World Health Organization . Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series, No.843. Geneva: WHO; 1994.

15.

15 Eastell R Reid DM Compston J . A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 1998; 244: 271–292.

16.

16 Chan SP Malik M Goh E . Prevalence of vitamin D inadequacy among community dwelling postmenopausal Malaysian women with osteoporosis. Asian J Fed Endocr Soc 2005; 25(Suppl.): S78.

17.

17 Lips P Hosking D Lippuner K . The prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigation. J Intern Med 2006; 260: 245–254.

18.

18 Pineau CA Urowitz MB Fortin PJ Ibanez D Gladman DD . Osteoporosis in systemic lupus erythematosus: factors associated with referral for bone mineral density studies, prevalence of osteoporosis and factors associated with reduced bone density. Lupus 2004; 13: 436–441.

19.

19 Lee C Almagor O Dunlop DD . Disease damage and low bone mineral density: an analysis of women with systemic lupus erythematosus ever and never receiving corticosteroids. Rheumatology (Oxford) 2006; 45: 53–60.

20.

20 Chong HC Chee SS Goh EML Chow SK Yeap SS . Dietary calcium and bone mineral density in premenopausal women with systemic lupus erythematosus. Clin Rheumatol 2007; 26: 182–185.

21.

21 Bultink IE Lems WF Kostense PJ Dijkmans BA Voskuyl AE . Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 54: 2044–2050.

22.

22 Borba VZ Matos PG da Silva Viana PR Fernandes A Sato EI Lazaretti-Castro M . High prevalence of vertebral deformity in premenopausal systemic lupus erythematosus patients. Lupus 2005; 14: 529–533.